CS
PHAT icon

Credit Suisse’s Phathom Pharmaceuticals PHAT Stock Holding History

Credit Suisse’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$421K Buy
39,683
+1,647
+4% +$14K ﹤0.01% 2709
2023
Q4 		$347K Sell
38,036
-2
-0% -$17 ﹤0.01% 2887
2023
Q3 		$394K Sell
38,038
-1,426
-4% -$19.6K ﹤0.01% 2814
2023
Q2 		$565K Buy
39,464
+22,803
+137% +$263K ﹤0.01% 2711
2023
Q1 		$119K Buy
16,661
+1,216
+8% +$10.7K ﹤0.01% 3188
2022
Q4 		$173K Buy
15,445
+4,633
+43% +$47.8K ﹤0.01% 3222
2022
Q3 		$120K Buy
10,812
+491
+5% +$4.68K ﹤0.01% 3398
2022
Q2 		$88K Buy
+10,321
New +$106K ﹤0.01% 3562
2021
Q4 		– Sell
-8,429
Closed -$271K – 4635
2021
Q3 		$271K Buy
8,429
+1,830
+28% +$60.8K ﹤0.01% 4125
2021
Q2 		$224K Buy
6,599
+1,233
+23% +$44.2K ﹤0.01% 4243
2021
Q1 		$202K Sell
5,366
-2,560
-32% -$107K ﹤0.01% 4119
2020
Q4 		$264K Buy
+7,926
New +$321K ﹤0.01% 4021

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Credit Suisse's PHAT Position: Q1 2024 in Review

Credit Suisse increased its Phathom Pharmaceuticals (PHAT) stake by 4.3% in Q1 2024, buying an estimated $14K and bringing the position to 39,683 shares worth $421K. The position accounts for ﹤0.01% of the portfolio, ranked #2709.

Credit Suisse first reported a position in PHAT in Q4 2020 and has held it in 12 quarters since. The position peaked at $565K in Q2 2023. 114 funds tracked by Wall St. Rank hold PHAT as of Q1 2024.

  • Credit Suisse held 39,683 shares of Phathom Pharmaceuticals worth $421K as of Q1 2024.
  • Credit Suisse bought 1,647 Phathom Pharmaceuticals shares in Q1 2024, an estimated $14K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2709 holding.
  • Credit Suisse first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
  • Credit Suisse's Phathom Pharmaceuticals position peaked at $565K in Q2 2023.
  • 114 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.